Delaware court rules against Gilead and Astellas in years-long patent case
A judge in Delaware has ruled against Astellas Pharma and Gilead in a long-running patent case over Pfizer-onwed Hospira’s generic version of Lexiscan.
The case kicked off in 2018, after Hospira submitted an Abbreviated New Drug Application (ANDA) for approval to market a generic version of Gilead’s Lexiscan. The drug is used in myocardial perfusion imaging (MPI), a type of nuclear stress test.
Gilead and Astellas alleged that Hospira’s ANDA submission for regadenoson infringed upon several patents, and sought a declaratory judgment that Hospira’s manufacturing of the product would constitute a direct and induced infringement. Hospira denied the allegations, asserting in its defense that the patents are invalid and filing counterclaims seeking judgments of noninfringement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.